Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Accenture
Harvard Business School
Moodys
Novartis
Express Scripts
Healthtrust
Colorcon
AstraZeneca
Johnson and Johnson

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,658,676

« Back to Dashboard

Which drugs does patent 8,658,676 protect, and when does it expire?

Patent 8,658,676 protects CLEVIPREX and is included in one NDA.

This patent has nineteen patent family members in fifteen countries.
Summary for Patent: 8,658,676
Title:Clevidipine emulsion formulations containing antimicrobial agents
Abstract: Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.
Inventor(s): Motheram; Rajeshwar (Dayton, NJ), Williams; Gregory Charles (Bernardsville, NJ)
Assignee: The Medicines Company (Parsippany, NJ)
Application Number:13/765,613
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 8,658,676

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-001 Aug 1, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-002 Aug 1, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-003 Nov 8, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,658,676

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand 610465 ➤ Sign Up
Mexico 2013004151 ➤ Sign Up
South Korea 20130101080 ➤ Sign Up
South Korea 101786857 ➤ Sign Up
South Korea 20160032266 ➤ Sign Up
Japan 2016183183 ➤ Sign Up
Japan 2014196322 ➤ Sign Up
Japan 6040437 ➤ Sign Up
Japan 2014504259 ➤ Sign Up
Hungary E026295 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Deloitte
McKinsey
US Army
Cerilliant
UBS
Mallinckrodt
Fish and Richardson
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot